|
|
纯中药治疗雄激素抵抗的复发难治性前列腺癌1例
|
Abstract:
前列腺癌发生远处转移的概率可高达70%，骨转移是最常见的。目前，转移性前列腺癌的治疗主要是内分泌治疗，但几乎所有患者都会出现激素抵抗，使疾病复发且治疗难度大幅提升。本文通过单纯中药治疗一例复发难治性前列腺癌，旨在为雄激素抵抗的复发难治性前列腺癌的治疗提供了新的治疗思路和转机。
The probability of distant metastasis of prostate cancer can be as high as 70%, with bone metastasis being the most common. Currently, the treatment of metastatic prostate cancer is mainly endocrine therapy, but almost all patients develop hormone resistance, which makes the disease recurrent and the difficulty of treatment substantially increased. This paper aims to provide a new therapeutic idea and turnaround for the treatment of castration-resistance relapsed refractory prostate cancer through the treatment of a case of relapsed refractory prostate cancer by simple traditional Chinese medicine.
| [1] | Gandaglia, G., Abdollah, F., Schiffmann, J., Trudeau, V., Shariat, S.F., Kim, S.P., et al. (2013) Distribution of Metastatic Sites in Patients with Prostate Cancer: A Population-Based Analysis. The Prostate, 74, 210-216. https://doi.org/10.1002/pros.22742 |
| [2] | Awang, Z.H., Essler, M. and Ahmadzadehfar, H. (2018) Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Current Approaches. Radiation Oncology, 13, Article No. 98. https://doi.org/10.1186/s13014-018-1037-7 |
| [3] | Kyriakopoulos, C.E., Chen, Y., Carducci, M.A., Liu, G., Jarrard, D.F., Hahn, N.M., et al. (2018) Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of Clinical Oncology, 36, 1080-1087. https://doi.org/10.1200/jco.2017.75.3657 |
| [4] | Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., et al. (2022) Abiraterone Plus Prednisone Added to Androgen Deprivation Therapy and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer (PEACE-1): A Multicentre, Open-Label, Randomised, Phase 3 Study with a 2×2 Factorial Design. The Lancet, 399, 1695-1707. https://doi.org/10.1016/s0140-6736(22)00367-1 |
| [5] | Rathkopf, D.E., Smith, M.R., de Bono, J.S., Logothetis, C.J., Shore, N.D., de Souza, P., et al. (2014) Updated Interim Efficacy Analysis and Long-Term Safety of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Patients without Prior Chemotherapy (COU-AA-302). European Urology, 66, 815-825. https://doi.org/10.1016/j.eururo.2014.02.056 |
| [6] | Zhang, Z., Wei, M., Mai, L., Li, Y., Wu, J., Huang, H., et al. (2020) Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients with Metastatic Prostate Cancer. Frontiers in Oncology, 10, Article 549220. https://doi.org/10.3389/fonc.2020.549220 |
| [7] | Sweeney, C.J., Martin, A.J., Stockler, M.R., Begbie, S., Chi, K.N., Chowdhury, S., et al. (2021) Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 80, 275-279. https://doi.org/10.1016/j.eururo.2021.05.016 |
| [8] | Kintzel, P.E., Chase, S.L., Schultz, L.M. and O'Rourke, T.J. (2008) Increased Risk of Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 28, 1511-1522. https://doi.org/10.1592/phco.28.12.1511 |
| [9] | Grisay, G., Lavaud, P. and Fizazi, K. (2024) Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer. Current Oncology Reports, 26, 488-495. https://doi.org/10.1007/s11912-024-01509-6 |
| [10] | Basch, E., Autio, K., Ryan, C.J., Mulders, P., Shore, N., Kheoh, T., et al. (2013) Abiraterone Acetate Plus Prednisone versus Prednisone Alone in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer: Patient-Reported Outcome Results of a Randomised Phase 3 Trial. The Lancet Oncology, 14, 1193-1199. https://doi.org/10.1016/s1470-2045(13)70424-8 |
| [11] | De Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011) Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine, 364, 1995-2005. https://doi.org/10.1056/nejmoa1014618 |
| [12] | Antonarakis, E.S., Piulats, J.M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C.J., et al. (2020) Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Journal of Clinical Oncology, 38, 395-405. https://doi.org/10.1200/jco.19.01638 |
| [13] | Zhang, W., Zhang, B. and Chen, X. (2021) Adjuvant Treatment Strategy after Curative Resection for Hepatocellular Carcinoma. Frontiers of Medicine, 15, 155-169. https://doi.org/10.1007/s11684-021-0848-3 |
| [14] | Yang, J., Zhu, L., Wu, Z. and Wang, Y. (2013) Chinese Herbal Medicines for Induction of Remission in Advanced or Late Gastric Cancer. Cochrane Database of Systematic Reviews, No. 4, CD005096. https://doi.org/10.1002/14651858.cd005096.pub4 |
| [15] | Wang, L., Ke, J., Wang, C., Li, Y., Wu, G., Ding, Q., et al. (2020) Efficacy and Safety of Banxia Xiexin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients with Advanced Hepatocellular Carcinoma. Integrative Cancer Therapies, 19, 88-93. https://doi.org/10.1177/1534735420942587 |
| [16] | Zhai, B., Zhang, N., Han, X., Li, Q., Zhang, M., Chen, X., et al. (2019) Molecular Targets of Β-Elemene, a Herbal Extract Used in Traditional Chinese Medicine, and Its Potential Role in Cancer Therapy: A Review. Biomedicine & Pharmacotherapy, 114, Article 108812. https://doi.org/10.1016/j.biopha.2019.108812 |
| [17] | Wade, C. and Kyprianou, N. (2018) Profiling Prostate Cancer Therapeutic Resistance. International Journal of Molecular Sciences, 19, Article 904. https://doi.org/10.3390/ijms19030904 |
| [18] | 王苏美, 吴万垠. 中药复方治疗肿瘤的研究进展及存在问题探讨[J]. 中医肿瘤学杂志, 2022, 4(6): 59-65. |
